T. Rowe Price Investment Management
TNGX icon

T. Rowe Price Investment Management’s Tango Therapeutics TNGX Stock Holding History

T. Rowe Price Investment Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.21M Sell
440,015
-6,198
-1% -$86.3K 0.01% 540
2025
Q4 		$3.95M Sell
446,213
-3,080,146
-87% -$26.5M ﹤0.01% 585
2025
Q3 		$29.6M Buy
3,526,359
+357,133
+11% +$2.42M 0.02% 461
2025
Q2 		$16.2M Sell
3,169,226
-143,223
-4% -$354K 0.01% 525
2025
Q1 		$4.54M Sell
3,312,449
-33,102
-1% -$81.3K ﹤0.01% 589
2024
Q4 		$10.3M Sell
3,345,551
-1,677,595
-33% -$7.79M 0.01% 551
2024
Q3 		$38.7M Buy
5,023,146
+267,167
+6% +$2.55M 0.02% 442
2024
Q2 		$40.8M Buy
4,755,979
+434,428
+10% +$3.36M 0.03% 420
2024
Q1 		$34.3M Buy
4,321,551
+4,034,857
+1,407% +$43.2M 0.02% 449
2023
Q4 		$2.84M Buy
+286,694
New +$2.49M ﹤0.01% 542

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

T. Rowe Price Investment Management's TNGX Position: Q1 2026 in Review

T. Rowe Price Investment Management reduced its Tango Therapeutics (TNGX) stake by 1.4% in Q1 2026, selling an estimated $86.3K and leaving 440,015 shares worth $9.21M. The position accounts for 0.01% of the portfolio, ranked #540.

T. Rowe Price Investment Management first reported a position in TNGX in Q4 2023 and has held it in 10 quarters since. The position peaked at $40.8M in Q2 2024. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • T. Rowe Price Investment Management held 440,015 shares of Tango Therapeutics worth $9.21M as of Q1 2026.
  • T. Rowe Price Investment Management sold 6,198 Tango Therapeutics shares in Q1 2026, an estimated $86.3K.
  • Tango Therapeutics made up 0.01% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #540 holding.
  • T. Rowe Price Investment Management first reported a position in Tango Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • T. Rowe Price Investment Management's Tango Therapeutics position peaked at $40.8M in Q2 2024.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.